Stock Code: 301290 Stock Abbreviation: Dongxing Medical Announcement No.: 2026-031
Jiangsu Dongxing Intelligent Medical Technology Co., Ltd. (hereinafter referred to as the "Company," "Listed Company," or "Dongxing Medical") received the "Inquiry Letter on the Restructuring of Jiangsu Dongxing Intelligent Medical Technology Co., Ltd." (Growth Enterprise Market M&A Inquiry Letter [2026] No. 5) (hereinafter referred to as the "Inquiry Letter") from the Shenzhen Stock Exchange on May 26, 2026.
In accordance with the requirements of the Inquiry Letter, the listed company and relevant intermediaries have conducted a thorough analysis and verification of the issues, implemented them item by item, and made supplementary disclosures in the "Report on Major Asset Purchase of Jiangsu Dongxing Intelligent Medical Technology Co., Ltd. (Draft) (Revised)" (hereinafter referred to as the "Restructuring Report"). The relevant responses are explained as follows.
Unless otherwise specified, the abbreviations or definitions used in this response to the Inquiry Letter have the same meanings as those defined in the "Definitions" section of the Restructuring Report.
The financial data in this response are rounded to two decimal places. Any discrepancies between the totals and the sums of the individual items are due to rounding.
Font used in this response:
Inquiry Letter Questions: Bold
Responses to Inquiry Letter Questions: Songti (Non-bold)
Supplementary Disclosure Content: Kaiti (Bold)
Question 1
The report shows that this transaction adopts a cash payment method with a transaction consideration of 769.5 million yuan, funded by the reallocation of partial IPO proceeds and self-owned or self-raised funds. As of the end of 2025, your company's cash balance was 78 million yuan, and the balance of trading financial assets was 1.197 billion yuan. Please explain:
(1) Combined with the specific products, amounts, maturity dates, daily operating capital requirements, and investment/financing arrangements of the trading financial assets, explain the necessity and rationality of changing the use of raised funds to pay the cash consideration, and whether it complies with the relevant regulations on the supervision of raised funds of listed companies.
(2) Explain whether the source of funds for this transaction involves borrowing. If so, please explain the name of the lender, amount, interest rate, repayment plan, source of repayment funds, and progress as of the date of the reply.
(3) Quantitatively analyze the impact of this transaction on the company's cash flow and explain whether it will lead to material adverse changes in the financial condition of the listed company.
Please have the financial advisor verify and express a clear opinion.
Response:
I. Combined with the specific products, amounts, maturity dates, daily operating capital requirements, and investment/financing arrangements of the trading financial assets, explain the necessity and rationality of changing the use of raised funds to pay the cash consideration, and whether it complies with the relevant regulations on the supervision of raised funds of listed companies.
As of the end of 2025, the specific status of the company's trading financial assets is as follows:
Unit: 10,000 Yuan